Sunday Research Poster Presentations

Poster Display Hours – 12:30 PM - 7:30 PM Poster Author Discussion Hour – 6:30 PM - 7:30 PM

POSTER PRESENTATIONS: PHP: HEALTH CARE USE & POLICY STUDIES ROWS A-N PGI: GASTROINTESTINAL DISORDERS ROWS N-O PMH: MENTAL HEALTH ROWS O-R PSS: SENSORY SYSTEMS DISORDERS ROWS R-S PUK URINARY/KIDNEY DISORDERS ROWS S-T

Research Poster Presentations Acceptance Code PDF Page # Topic – Subtopic PHP1-PHP3 21 Health Care Use & Policy Studies - Consumer Role in Health Care PHP4-PHP26 22 Health Care Use & Policy Studies - Drug/Device/Diagnostic Use & Policy PHP27-PHP29 31 Health Care Use & Policy Studies - Equity and Access PHP30-PHP32 33 Health Care Use & Policy Studies - Formulary Development PHP33-PHP73 34 Health Care Use & Policy Studies - Health Care Costs & Management PHP74-PHP105 51 Health Care Use & Policy Studies - Health Care Research & Education PHP106-PHP115 63 Health Care Use & Policy Studies - Health Technology Assessment Programs PHP116-PHP117 68 Health Care Use & Policy Studies - Population Health PHP118-PHP121 69 Health Care Use & Policy Studies - Prescribing Behavior & Treatment Guidelines PHP122-PHP123 70 Health Care Use & Policy Studies - Quality of Care PHP124-PHP125 71 Health Care Use & Policy Studies - Regulation of Health Care Sector PHP126-PHP129 72 Health Care Use & Policy Studies - Risk Sharing/Performance-Based Agreements PHP130-PHP136 74 Health Care Use & Policy Studies - Conceptual Papers

PGI1-PGI2 76 Gastrointestinal Disorders - Clinical Outcomes Studies PGI3-PGI6 77 Gastrointestinal Disorders - Cost Studies PGI7-PGI9 79 Gastrointestinal Disorders - Patient-Reported Outcomes & Patient Preference Studies PGI10-PGI15 80 Gastrointestinal Disorders - Health Care Use & Policy Studies

PMH1-PMH7 82 Mental Health - Clinical Outcomes Studies PMH8-PMH16 85 Mental Health - Cost Studies PMH17-PMH22 89 Mental Health -Reported Outcomes & Patient Preference Studies PMH23-PMH26 91 Mental Health - Health Care Use & Policy Studies

PSS1-PSS 93 Sensory Systems Disorders - Clinical Outcomes Studies PSS2-PSS4 93 Sensory Systems Disorders - Cost Studies PSS5-PSS9 95 Sensory Systems Disorders - Patient-Reported Outcomes & Patient Preference Studies PSS10-PSS11 97 Sensory Systems Disorders - Health Care Use & Policy Studies

PUK1-PUK3 98 Urinary/Kidney Disorders - Clinical Outcomes Studies PUK4-PUK8 99 Urinary/Kidney Disorders - Cost Studies PUK9-PUK13 101 Urinary/Kidney Disorders - Patient-Reported Outcomes & Patient Preference Studies PUK14-PUK16 103 Urinary/Kidney Disorders - Health Care Use & Policy Studies

HEALTH C RESEARCH POSTER PRESENTATIONS - SESSION I HEALTH CARE USE & POLICY STUDIES

HEALTH CARE USE & POLICY STUDIES - Consumer Role in Health Care

PHP1 A1 SELF-MEDICATION WITH ANTIBIOTICS IN SANA'A CITY

Albawani S, Gnanasan S, Abd. Aziz N, Hassan Y,Universiti Teknologi MARA, Puncak Alam, Malaysia

PHP2 A2 SCHOOLS' PERSPECTIVE ON PROMOTING RATIONAL USE OF ANTIBIOTICS IN NEW DELHI, INDIA – A QUALITATIVE STUDY

Kotwani A, Holloway K,WHO-SEARO, New Delhi, India

PHP3 A3 COMPARISION OF PERCEPTION TOWRDS GENERIC MEDICINES BETWEEN FINAL YEAR PHARMACY AND MEDICAL STUDENTS IN SOUTHEAST YEMEN

AL-Tamimi SK1, Hassali MA

1, Shafie AA

1, Alrasheedy AA

2,1Universiti Sains Malaysia, Penang, Malaysia,

2Qassim University,

Qassim, Saudi Arabia

HEALTH CARE USE & POLICY STUDIES - Drug/Device/Diagnostic Use & Policy

PHP4 A4 APPLICATION OF MULTI-CRITERIA DECISION ANALYSIS (MCDA) SCORING AS AN HTA METHODOLOGY FOR OFF-PATENT PHARMACEUTICALS (OPP) IN EMERGING MARKETS

Brixner D1, Maniadakis N

2, Kaló Z

3, Hu S

4, Johnston A

5, Shen J

6, Wijaya KE

7,1Personalized Health Care, University of Utah

Health Sciences Center, Salt Lake City, UT, USA, 2National School Of Public Health, Athens, Greece,

3Eötvös Loránd University,

Budapest, Hungary, 4Fudan University, Shanghai, China,

5Queen Mary University of London, London, UK,

6Abbott Laboratories,

Abbott Park, IL, USA, 7Abbott Laboratories, Allschwil, Switzerland

PHP5 A5 ARE US PRIVATE PAYERS' MEDICAL POLICIES INFLUENCED BY COCHRANE EVIDENCE?

Singh A1, Hussain S

2, Najmi AK

2,1Independent Researcher, New Delhi, India,

2Faculty of Pharmacy, Jamia Hamdard, Hamdard

University, New Delhi, India

PHP6 A6 ‘SEVERE ILLNESS INSURANCE' IN CHINA: IMPACT OF THE NEW COVERAGE ON ACCESS TO HEALTH CARE AND INNOVATIVE DRUGS

Sherwin G, Akpinar P, Yap B, Li X,ICON plc, LONDON, UK

PHP7 A7 FREE ESSENTIAL MEDICINES THROUGH PUBLIC HEALTH FACILITIES IN NEPAL: A QUALITATIVE STUDY

Acharya M1, Dahal A

2,1University of Arkansas for Medical Sciences, Little Rock, AR, USA,

2The University of Toledo, Toledo,

OH, USA

PHP9 A8 SUGGESTION ON CRITICAL ILLNESS INSURANCE IN CHINA

Zhu L, Xu H, Cui X,Sanofi China, Shanghai, China

PHP10 A9 ONLINE PHARMACY REGULATION IN INDIA: A CROSS SECTIONAL SURVEY ON PERCEPTIONS OF HEALTH CARE STUDENTS/PROFESSIONALS

Peringadi Vayalil M, Rajesh V, Rajan MS, Girish T,Manipal University, Manipal, Udupi Dist., India

PHP11 A10 DEVELOPMENT OF HOSPITAL FORMULARY IN JAPAN - CURRENT TRENDS AND ISSUES

Hamashima Y1, Hamashima C

2,1University of Tokyo Hospital, Tokyo, Japan,

2National Cancer Center, Tokyo, Japan

PHP12 B1 HOW DOES PRICING AND ACCESS OF INNOVATIVE ONCOLOGY AGENTS IN CHINA COMPARE WITH OTHER ASIAN MARKETS?

Sherwin G, Akpinar P, Yap B, Lu V, Im Y,ICON plc, LONDON, UK

PHP13 B2 WHAT IMPACT IS THE EVOLVING HEALTH CARE LANDSCAPE HAVING ON ACCESS TO INNOVATIVE MEDICINES IN CHINA?

Sherwin G, Akpinar P, Yap B,ICON plc, LONDON, UK

PHP14 B3 ASSESSMENT OF BIOSIMILAR LANDSCAPE IN KOREA, MALAYSIA, SINGAPORE AND TAIWAN

Chen S1, Conti CC

2, Cheong J

1,1GfK Singapore, Singapore, Singapore,

2GfK, London, UK

PHP15 B4 THE PRICING AND REIMBURSEMENT OF SPECIALTY DRUGS IN KEY ASIAN MARKETS

Subramanian D, Dummett H,EMAX Solutions, Singapore, Singapore

PHP16 B5 BUILDING INTENTIONS WITH THE THEORY OF PLANNED BEHAVIOUR: THE MEDIATING ROLE OF KNOWLEDGE AND EXPECTATIONS IN SUCCESSFUL NEW PHARMACY PUBLIC HEALTH SERVICES IMPLEMENTATION

Hoay TL1, Hassali MA

1, Gan V

2, Saleem F

1,1Universiti Sains Malaysia, Penang, Malaysia,

2Universiti Putra Malaysia, Serdang,

Malaysia

PHP17 B6 GENERAL PUBLIC KNOWLEDGE AND AWARENESS ABOUT MEDICINES USE IN PENANG, MALAYSIA

Dawood OT, Hassali MA, Saleem F,Universiti Sains Malaysia, Penang, Malaysia

PHP18 B7 QUINOLONES UTILIZATION IN TWO TERTIARY HOSPITALS IN NIGERIA; A PHARMACOEPIDEMIOLOGICAL SURVEY

Ogbonna B1, Eze L

1, Ogbonna C

2, Ejim C

2,1NNAMDI AZIKIWE UNIVERSITY, ANAMBRA STATE, Nigeria,

2ENUGU STATE

UNIVERSITY TEACHING HOSPITAL, ENUGU, NIGERIA, ENUGU, Nigeria

PHP19 B8 ATTITUDE TOWARDS THE USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINES (CAM) AMONG PHARMACY AND MEDICAL STUDENTS. A COMPARATIVE STUDY

Farooqui M1, Othman CN

1, Sadeeqa S

2, Farooqui MA

3, ul Haq N

4,1Universiti Teknologi MARA (UiTM), Kepala Batas,

Malaysia, 2Institute of Pharmacy, Lahore, Pakistan,

3Kolej Universiti Insaniah, Kuala Ketil, Kedah,, Malaysia,

4University of

Balochistan, Quetta, Pakistan

PHP20 B9 DRUG UTILIZATION IN AN OUTPATIENT PRIVATE PAEDIATRIC SETTING: AN OBSERVATIONAL STUDY

Deshwal S1, Tiwari P

1, Kumar N

2,1National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali),

Punjab, India, 2Chaitanya Hospital, Chandigarh, India

PHP21 B10 DRUG UTILIZATION STUDY OF ANTIBIOTICS IN A SECONDARY CARE REFERRAL HOSPITAL

Rathikanti V,chalapathi institute of pharmaceutical sciences, Vijayawada, India

PHP22 C1 PERLIMINARY STUDY OF MEDICATION REGIMEN COMPLEXITY AMONG TAIWANESE ELDERLY WHO HAVE USED ANXIETY OR HYPNOTICS PRESCRIPTIONS

Chen J1, Simonavice CA

2, Chen Y

2, Lin H

1,1China Medical University, Taichung, Taiwan,

2China Medical University Hospital,

Taichung, Taiwan

PHP23 C2 WHAT DO WE PAY FOR COMPOUNDED DRUGS?

Lin T1, Tran DM

2, Shoair OA

2, Huang W

1, Cao V

1, Wilson L

2,1UCSF, San Francisco, CA, USA,

2University of California, San

Francisco, San Francisco, CA, USA

PHP24 C3 A NATIONWIDE SURVEY ON INFECTION CONTROL ACTIVITIES WITHIN HOSPITALS ALLOWED TO IMPLEMENT PREFERENTIAL INFECTION PREVENTION COUNTERMEASURE FEE IN JAPAN

Hirose M1, Nishimura N

2, Naora K

2, Imanaka Y

3,1Shimane University, Izumo, Japan,

2Shimane University Hospital, Izumo,

Japan, 3Kyoto University, Kyoto, Japan

PHP25 C4 ASSOCIATION OF SOCIOECONOMIC CONDITIONS AND DRUG OFFENCES AND REINCARCERATION

Huang C, Yang M,National Taiwan University, Taipei, Taiwan

PHP26 C5 ASSESSMENT OF PRESCRIBING INDICATORS IN PUBLIC AND PRIVATE PRIMARY HEALTH CARE FACILITIES IN INDONESIA

Yuniar Y, Susyanty AL, Sari ID,National Institute of Health Research and Development, Central Jakarta, Indonesia

HEALTH CARE USE & POLICY STUDIES - Equity and Access

PHP27 C6 A REVIEW OF PHARMECEUTICAL POLICIES IN RESPONSE TO ECONOMIC CRISIS AND SANCTIONS

Kheirandish M,Tehran university of medical sciences, tehran, Iran (Islamic Republic of)

PHP28 C7 EQUITY OF GOVERNMENT SUBSIDY IN HEALTH CARE: A CASE STUDY IN CHINA

Si L1, Chen M

2, Palmer AJ

3,1University of Tasmaina, Hobart, Australia,

2Nanjing Medical Univeristy, Nanjing, China,

3Menzies

Institute for Medical Research, Hobart, Australia

PHP29 C8 DEVELOPING HTA GUIDELINES FOR RARE DISEASE THERAPIES - AN INDUSTRY PERSPECTIVE

Taylor CB1, Weston AR

1, Milliner C

2, Schulz S

2, Clark F

3, Goodall A

3, Brown A

4, Chim L

5, Kwasha D

5, Quinn E

6, McDonnell T

7,

Evans K8,1Asia Pacific, Sydney, Australia,

2Shire, North Ryde, Australia,

3Sanofi Genzyme, Macquarie Park, Australia,

4Sanofi

Australia, Macquarie Park, Australia, 5Alexion Pharmaceuticals Australasia, Frenchs Forest, Australia,

6Vertex Pharmaceuticals

(Australia), St Leonards, Australia, 7A. Menarini Australia, Chatswood, Australia,

8BioMarin Pharmaceutical Australia, Crows

Nest, Australia

HEALTH CARE USE & POLICY STUDIES - Formulary Development

PHP31 C9 WHAT'S NEW IN THE GUIDELINES FOR SUBMISSION OF DOSSIER FOR LISTING INTO THE MINISTRY OF HEALTH MEDICINES FORMULARY (MOHMF) ?

Low EV, Ramli A, Lajis R, Aryani Md Yusof F,Ministry of Health Malaysia, Petaling Jaya, Malaysia

PHP32 C10 TEMPERATURE, REAL TIME, ON SITE, POTENCY MONITORING STUDIES OF DIFFERENT BRANDS OF CEPHALEXIN TABLETS STORED IN HOSPITAL AND COMMUNITY PHARMACIES IN DIFFERENT PART OF KERALA

Kiron sS,academy of pharmaceutical sciences, kannur, India

HEALTH CARE USE & POLICY STUDIES - Health Care Costs & Management

PHP33 D1 CONSTRUCTION OF SYSTEM DYNAMICS MODEL FOR MEDICAL CARE SYSTEM OF JAPAN

Inoue S1, Xu H

2, Maswana J

2, Kobayashi M

1,1CRECON Medical Assessment Inc., Tokyo, Japan,

2University of Tsukuba, Tokyo,

Japan

PHP34 D2 THE STUDY OF DRUG PRICE COMPRISON BETWEEN CHINA AND 14 OTHER COUNTRIES

Liu B1, Su W

2, Mo Y

1,1Department of Health Economics, School of Public Health, Fudan University, Shanghai, China,

2IHS Life

Sciences, Washington, DC, USA

PHP35 D3 THE FIRST INDONESIAN HEALTH-RELATED QUALITY OF LIFE VALUATION STUDY: AN EQ-5D-5L VALUE SET

Purba FD1, Hunfeld J

1, Iskandarsyah A

2, Fitriana TS

3, Sadarjoen SS

2, Passchier J

4, van Busschbach J

1,1Erasmus MC,

Rotterdam, The Netherlands, 2Padjadjaran University, Jatinangor, Indonesia,

3YARSI University, Jakarta, Indonesia,

4VU

University, Amsterdam, The Netherlands

PHP36 D4 COST VARIATIONS OF INPATIENT, DAYCARE AND OUTPATIENT HYSTEROSCOPY IN A TERTIARY-CARE HOSPITAL IN MALAYSIA

Shabaruddin FH, Chai BS, Woo YL, Dahlui M,University of Malaya, Kuala Lumpur, Malaysia

PHP37 D5 SPIRALLING HEALTHCARE EXPENDITURE IN MALAYSIA: IS IT SUSTAINABLE?

Perumal AK,B. Braun, KL, Malaysia

PHP38 D6 UNIVERSAL HEALTH COVERAGE IN COUNTRIES ACROSS EAST AND SOUTHEAST ASIA – ASSOCIATIONS BETWEEN HEALTH EXPENDITURE AND SERVICE PROVISION

Evans JS, Wickstead RM, Hanman K, Steeves S,Costello Medical Consulting Ltd, Cambridge, UK

PHP39 D7 THE IMPACTS OF CASE PAYMENT IN RURAL HAINAN OF CHINA

He L, Yang L,Peking University, Beijing, China

PHP40 D8 COSTS AND BENEFITS OF HOME FOOD INDUSTRY ISSUANCE PROGRAM IN INDONESIA

Sucahya pK1, Sari K

2,1Center for Health Research Universitas Indonesia, Depok, Indonesia,

2Center for Health Economics and

Policy Studies Universitas Indonesia, Depok, Indonesia

PHP41 D9 EXPERIENCE SEEKING APPROPRIATE STANDARDS OF COST-EFFECTIVENESS RATIO: UPDATES AND CHALLENGES IN JAPANESE SETTING

Kamae I, Sugimoto T,The University of Tokyo, Graduate School of Public Policy, Tokyo, Japan

PHP42 D10 ICT DIFFUSION AND PHARMACEUTICALS (ISSUES FOR DECISION TOOLS)

Huttin CC,Endepusresearchinc and Univ Aix Marseille, Cambridge, MA, USA

PHP43 E1 APPLICATION LIMITATIONS OF COST MINIMIZATION ANALYSIS IN CHINA

Zhu L, Cui X, Xu H,Sanofi China, Shanghai, China

PHP44 E2 RISK OF DISCONTINUATION OF ADVANCED THERAPY MEDICINAL PRODUCTS CLINICAL TRIALS

Hanna E1, Rémuzat C

2, Toumi M

1,1Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille,

France, 2Creativ-Ceutical, Paris, France

PHP45 E3 OUTCOMES FROM HOMEOPATHIC PRESCRIBING IN SECONDARY CARE HOMEOPATHIC HOSPITAL: A PROSPECTIVE STUDY

Dobariya N1, Tiwari P

1, Dhiman K

2, Sareen P

2, Anand T

2, Sharda S

2, Manku Tk

2, Kaur R

2,1National Institute of Pharmaceutical

Education and Research (NIPER), S.A.S. Nagar (Mohali), Punjab, India, 2Homeopathic Medical College and Hospital,

Chandigarh, India

PHP46 E4 HIGH-RISK MEDICATIONS AND UNPLANNED HOSPITALIZATIONS: A CASE–TIME–CONTROL STUDY

Lin C1, Wen Y

2, Chen L

3, Hsiao F

1,1National Taiwan University, Taipei, Taiwan,

2Chang Gung University, Taoyuan,

Taiwan, 3Taipei Veterans General Hospital, Taipei, Taiwan

PHP47 E5 IMPLEMENTATION OF ADVERSE EVENT TRIGGER TOOL SYSTEM FOR ASSESSING PATIENT SAFETY

Vilakkathala R1, Mallayasamy S

1, K V

1, Rodrigues GS

2, BH AR

2,1Manipal University, Manipal, India,

2Kasturba Medical College,

Manipal, India

PHP48 E6 WHAT ARE THE KEY CONCERNS OF HEALTH CARE PROVIDERS IN CHINA? QUALITATIVE INVESTIGATION OF A DOUBLE-BLIND TELEPHONE SURVEY

Sun Y1, Liu GG

1, Wang T

2, You X

1, Zhao H

1,1Peking University, Beijing, China,

2Shenyang Pharmaceutical University,

Shenyang, China

PHP49 E7 FACTORS ASSOCIATED WITH 90-DAY OR 180-DAY LONG-TERM USE OF ANXIETY-HYPNOTIC PRESCRIPTIONS AND ECONOMIC AND SAFETY OUTCOMES: A RETROSPECTIVE COHORT STUDY

Lin H1, Tsai H

2, Liu F

3, Liao C

4, Li C

5, Lin C

4, Chou C

4, Chang C

4, Simonavice CA

4, Li T

1,1China Medical University, Taichung,

Taiwan, 2Providence University, Taichung City, Taiwan,

3Hsuan Chuang University, Hsinchu City, Taiwan,

4China Medical

University Hospital, Taichung, Taiwan, 5China Medical University Hospital, Taiwan, Taichung, Taiwan

PHP50 E8 EFFECTIVENESS OF TRIGGER TOOLS TO DETECT ADVERSE DRUG EVENTS FROM DISCHARGE SUMMARIES: A RETROSPECTIVE STUDY

Anburaj E1, Vilakkathala R

2, Mallayasamy S

2, Stanley W

2,1Manipal College of Pharmaceutical Sciences, Manipal,

India, 2Manipal University, Manipal, India

PHP51 E9 EVALUATION OF ATTITUDE AND PERCEPTION OF RETAIL PHARMACISTS TOWARDS PATIENT SAFETY

Sivanandy P, Marikannan M, Tan Tyng W, Tan Wee L, Lim Chong Y,International Medical University, Kuala Lumpur, Malaysia

PHP52 E10 IN-LICENSING AS A BUSINESS STRATEGY FOR PHARMACEUTICAL COMPANIES: A FRAMEWORK FOR THE NIGERIAN INDUSTRY

Keshi CB,UGSM-, Zug, Switzerland

PHP53 F1 A STUDY ON IDENTIFICATION, MONITORING AND MANAGEMENT OF ADVERSE DRUG REACTIONS IN A TERTIARY CARE HOSPITAL

Vudugu R, Eluka vL, Konuru V, Sagar SV, Kachapuram rC,St.Peter's Institute of Pharmaceutical Sciences, Hanamkonda, India

PHP54 F2 CHRONIC PATIENTS ATTITUDES, BELIEFS, AND EXPERIENCES REGARDING POLYPHARMACY AND WILLINGNESS TO DEPRESCRIBE IN QUETTA

ul Haq N, Mohaib M, Nasim A, Razaque G, Riaz S,University of Balochistan, Quetta, Pakistan

PHP55 F3 PERSONALIZED ADAPTIVE REWARDS VERSUS INCENTIVES TO MOTIVATE SUSTAINABLE HEALTHY BEHAVIORAL CHANGE- A NEO-MASLOWIAN CONCEPTUAL MODEL

Jones CA1, Clark EM

2, Weintraub A

1, Zia A

2,1University of Vermont College of Medicine, Burlington, VT, USA,

2University of

Vermont, Burlington, VT, USA

PHP56 F4 ADVERSE EVENTS ASSOCIATED WITH INTRAVENOUS IMMUNOGLOBULIN IN THAILAND

Sriphiromya P,Ministry of Public Health, Nonthaburi, Thailand

PHP57 F5 A STUDY OF PRESCRIPTION PATTERN OF NON STEROIDAL ANII-INFLAMMATORY DRUGS IN A TERTIARY CARE HOSPITAL

Thiruvengadarajan V1, Thattakudian Sheikuduman MS

2, Chakka G

2, Ramkanth S

1,1Annamacharya College of Pharmacy,

Kadapa, India, 2Annamacharya College of Pharmacy, YSR Kadapa, India

PHP58 F6 THE 2012 UPDATED BEERS CRITERIA IN FALLS RELATED HOSPITALIZATION IN OLDER ADULTS

Chen LL, Ng HT, Siow B, Ong KY, Tay JY, Cheen HH, Lim YL, Mamun K,Singapore General Hospital, Singapore, Singapore

PHP59 F7 EFFECT OF CLINICAL PHARMACIST IN PATIENT SAFETY:A PROSPECTIVE INTERVENTIONAL STUDY

Nafis MA, D Acharya L, Hande HM,Manipal University, Manipal, Udupi, India

PHP60 F8 THE EMERGING ROLES OF PHARMACISTS IN SELECTED TERTIARY HOSPITALS IN PANGASINAN AND LA UNION: FOCUS ON PHARMACEUTICAL CARE AND PHARMACOVIGILANCE

Cabral RP,Pangasinan State University, Urdaneta City, Philippines

PHP61 F9 A PROSPECTIVE ANALYSIS OF ADVERSE DRUG REACTION IN A TERTIARY CARE HOSPITAL

Ramesh S1, Prashant C

1, KrishnaPrabha C

2, Jai Ganesh KP

1, Manikandhan C

1, Sivakumar P

1, Sivasankar M

2,1Nehru College of

Pharmacy, Thrissur District, India, 2National College of Pharmacy, Kozhikode, India

PHP62 F10 DRUG UTILIZATION EVALUATION OF ANTIBIOTICS IN GENERAL MEDICINE DEPARTMENT OF A TERTIARY CARE HOSPITAL

Gowthami B1, Spurthi T

2,1JNTU, Anmantapur, kurnool, India,

2CES college of pharmacy, kurnool, India

PHP63 G1 REFORM OF CHINESE STATE-OWNED ENTERPRISE-AFFILIATED HOSPITAL

Wang T1, Li SC

2, Liu GG

3, Wu Z

1, Sun Y

3,1Shenyang Pharmaceutical University, Shenyang, China,

2The University of

Newcastle, Newcastle, Australia, 3Peking University, Beijing, China

PHP64 G2 ASSESSMENT OF CRITERIA INFLUENCES ON JUDICIOUS SELECTION OF NEW DRUG FOR FUTURE COVERAGE POLICY IN IRAN: AN ANALYSIS WITH STRUCTURAL EQUATION MODELING

Viyanchi A, Niasti F, Rabani T,Hamadan University of medical sciences, Hamadan, Iran

PHP65 G3 CONSOLIDATION OF CHINA'S TWO BASIC MEDICAL INSURANCE PROGRAMS: UNDERSTANDING NEW OPPORTUNITIES FOR ACCESS

MI M1, Suponcic S

2, LIU Y

1,1Navigant Life Sciences, Shanghai, China,

2Navigant Life Sciences, Lawrenceville, NJ, USA

PHP66 G4 IS THE LACK OF INCLUSION ON THE NATIONAL DRUG REIMBURSEMENT LIST THE END OF THE WORLD FOR ACCESS?

MI M1, Suponcic S

2, LIU Y

3,1Navigant Life Science, Shanghai, China,

2Navigant Life Sciences, Lawrenceville, NJ,

USA, 3Navigant Life Sciences, Shanghai, China

PHP67 G5 IMPROVING ACCESS TO NEW ONCOLOGY DRUGS IN THE CHINA MARKET: SHORTENTIME-TO-MARKET AND IMPROVE AFFORDABILITY

LIU Y1, Suponcic S

2, MI M

1,1Navigant Life Sciences, Shanghai, China,

2Navigant Life Sciences, Lawrenceville, NJ, USA

PHP68 G6 PATIENT ACCESS TO HIGH-COST AND HIGH-VALUE SPECIALTY PRODUCTS IN CHINA: REVIEW OF DECISIONS FROM ZHEJIANG, NEIMENGGU, SHANDONG AND JIANGXI

Gambari J, Chowdhury CA, Duttagupta S, Yang M,CBPartners, New York, NY, USA

PHP69 G7 UPCOMING REGULATIONS ON INSURANCE REIMBURSEMENT STANDARD IN CHINA: CHANLLANGES AND OPPORTUNITES FOR MNCS

MI M1, Suponcic S

2, Wang M

3, LIU Y

1,1Navigant Life Sciences, Shanghai, China,

2Navigant Life Sciences, Lawrenceville, NJ,

USA, 3Navigant Life Sciences, London, UK

PHP70 G8 A CASE STUDY ON THE DEVELOPMENT, IMPLEMENTATION AND OUTCOME OF CRITICAL DISEASE INSURANCE IN SHEN ZHEN, CHINA

Jiang J,Jinan University, Guangzhou, China

PHP71 G9 TITLE: ACCESS TO ORPHAN AND ULTRA-ORPHAN DRUGS IN CHINA

Gambari J, Yang M, Chowdhury CA, Duttagupta S,CBPartners, New York, NY, USA

PHP72 G10 HOW MUCH DO THE INSURED CITIZENS KNOW ABOUT THE PERSONAL ACCOUNT OF CHINA'S URBAN EMPLOYEES' BASIC MEDICAL INSURANCE AND WHAT ARE THEIR NEEDS? EVIDENCE FROM GUIZHOU, CHINA

Wu H1, Yi L

2, Ran X

1,1Guizhou Medical University, Guiyang, China,

2Department of human resources and social security of

Guizhou province, Guiyang, China

PHP73 H1 THE ROLE OF ECONOMIC EVIDENCE IN DRUG REIMBURSEMENT: SOUTH KOREA

Bae E1, Lee H

2, Kwon H

3, Yang B

4,1Gyeongsang National University, Jinju, South Korea,

2National Health Insurance Service,

Seoul, South Korea, 3Mokwon University, Daejeon, South Korea,

4Seoul National University, Seoul, South Korea

HEALTH CARE USE & POLICY STUDIES - Health Care Research & Education

PHP74 H2 EVALUATING THE RELATIVE EFFECTIVENESS OF TWO MALNUTRITION RISK ASSESSMENT TOOLS IN SURGICAL POPULATION AT A TERTIARY CARE HOSPITAL IN MALAYSIA

Khan OH1, Khan AH

1, Zakaria AD

2, Hashim MN

2, Sulaiman SA

1,1Universiti Sains Malaysia, Pulau Penang, Malaysia,

2Universiti

Sains Malaysia, Kota Bharu, Malaysia

PHP75 H3 VALUING HEALTH: RESULTS FROM THE HEALTH AUCTION VALUATION EXPERIMENT (HAVE) STUDY

Byrnes J1, Kularatna S

1, Scuffham P

2,1Griffith University, Meadowbrook, Australia,

2Griffith University, Gold Coast, Australia

PHP76 H4 THE STUDY OF THE EFFECT OF PHARMACY MANAGER'S MANAGERIAL SKILLS ON THE PERFORMANCE OF COMMUNITY PHARMACIES OF TEHRAN

Sehat S1, Mirjamali F

2, Rangchian M

3, Mehralian G

4, Salamzadeh J

5,1Islamic Azad University, Tehran, Iran (Islamic Republic

of), 2Shahid Beheshti University of Medical Sciences, Pharmacy School, Tehran, Iran (Islamic Republic of),

3Shahid Beheshti

University of Medical Sciences, School of Pharmacy, Tehran, Iran, 4Shahid Beheshti university of medical Sciences, School of

Pharmacy, Tehran, Iran, 5Shahid Beheshti University of Medical Sciences, School of Pharmacy, Tehran, Iran

PHP78 H5 PREDICTIVE VALIDITY OF NATIONAL NOSOCOMIAL INFECTION SURVEILLANCE (NNIS) AND STUDY ON THE EFFICACY OF NOSOCOMIAL INFECTIONS (SENIC) RISK INDEXES FOR THE INCIDENCE OF SURGICAL SITE INFECTIONS (SSI) IN GENERAL SURGERY AT HOSPITAL UNIVERSITI SAINS MALAYSIA (HUSM)

Khan OH1, Zakaria AD

2, Hashim MN

2, Sulaiman SA

1, Khan AH

1,1Universiti Sains Malaysia, Pulau Penang, Malaysia,

2Universiti

Sains Malaysia, Kota Bharu, Malaysia

PHP79 H6 ASSESSMENT OF COMMUNITY PHARMACY SERVICES IN MALAYSIA: PERSPECTIVES FROM COMMUNITY PHARMACISTS, GENERAL PRACTITIONERS, CONSUMERS AND HEALTH POLICY STAKEHOLDERS

Ooi GS1, Ahmad Hassali MA

2, Shafie AA

3, Kong DC

4, Mak V

5, Chua GN

2,1AIMST Univeristy, Bedong, Kedah,

Malaysia, 2Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia,

Penang, Malaysia, 3Universiti Sains Malaysia, Penang, Malaysia,

4Monash University, Victoria, Australia,

5Monash University

Malaysia, Selangor, Malaysia

PHP80 H7 MEDICATION ERRORS AVOIDED BY MEDICATION RECONCILIATION PROCESS AT FEMALE SURGERY WARD IN RAMATHIBODI HOSPITAL, THAILAND

Samarnkongsak T, Samankatiwat P,Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

PHP81 H8 EQ-5D UTILITY VALUE SETS FOR SRI LANKA: A CASE FOR ECONOMIC EVALUATIONS IN SOUTH ASIA

Kularatna S1, Byrnes J

1, Chen G

2, Scuffham P

3,1Griffith University, Meadowbrook, Australia,

2Flinders University, Adelaide,

Australia, 3Griffith University, Gold Coast, Australia

PHP82 H9 KNOWLEDGE, ATTITUDE AND PRACTICE (KAP) REGARDING BLOOD DONATION AMONG HEALTH CARE WORKERS IN MALAYSIA

Farooqui MA1, Yahaya BH

2, Hussien AR

2, Farooqui M

3,1Kolej Universiti Insaniah, Kuala Ketil, Kedah,, Malaysia,

2Universiti

Sains Malaysia, Bertam, Malaysia, 3Universiti Teknologi MARA (Bertam campus), Penang, Malaysia

PHP83 H10 HEALTH RELATED QUALITY OF LIFE FOR DISEASE POPULATION IN CHINA: A SYSTEMATIC REVIEW

Zhou T1, Guan HJ

2, Ma A

1, Liu GG

3,1China Pharmacuetical University, Nanjing, China,

2Peking University China Center for

Health Economic Research, Beijing, China, 3Peking University, Beijing, China

PHP84 I1 THE IMPACT OF DURATION ON EQ‐5D‐5L VALUE SETS DERIVED FROM A DISCRETE CHOICE EXPERIMENT

Norman R1, Mulhern B

2, Viney R

2, Bansback N

3, Pearce A

4,1Curtin University, Perth, Australia,

2University of Technology

Sydney, Sydney, Australia, 3University of British Columbia, Vancouver, BC, Canada,

4National Cancer Registry Ireland, Cork,

Ireland

PHP85 I2 USING BEST-WORST SCALING CHOICE EXPERIMENTS TO ELICIT THE MOST IMPORTANT DOMAINS OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN SINGAPORE

Uy EJ1, Bautista D

2, Xin X

1, Cheung YB

2, Thio S

1, Thumboo J

1,1Singapore General Hospital, Singapore, Singapore,

2Duke-NUS

Medical School, Singapore, Singapore

PHP86 I3 TRENDS IN JAPANESE CLINICAL TRIAL REGISTRATION FROM 2005 TO 2014

Sasaki M1, Fukuda T

2, Shiroiwa T

2, Igarashi A

3, Sato H

1,1National Institute of Public Health, Wako,, Japan,

2National Institute of

Public Health, Wako, Japan, 3University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan

PHP87 I4 A PUBMED BASED SEARCH ON COST EFFECTIVENESS AND HEALTH-RELATED QUALITY OF LIFE STUDIES WITH RESPECT TO COMPLEMENTARY AND ALTERNATIVE MEDICINES

Bhat B1, Sreedhar D

1, Udupa N

2,1Manipal College of Pharmaceutical Sciences, Manipal, India,

2Manipal University, Manipal,

India

PHP88 I5 DEVELOPING ITEM POOLS FOR PHYSICAL FUNCTIONING, SOCIAL RELATIONSHIPS, AND POSITIVE MINDSET TO MEASURE HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN THE SINGAPORE POPULATION

Uy EJ1, Xiao Y

1, Yeo PT

1, Xin X

1, Pua Y

1, Lee GL

2, Kwan YH

3, Vaingankar JA

4, Subramaniam M

4, Chan MF

5, Kumar N

5,

Bautista D3, Ow MY

3, Lim PA

1, Choo BE

1, Leung YY

1, Chan A

3, Sung SC

3, Kwek TC

1, Cheung YB

3, Thumboo J

1,1Singapore

General Hospital, Singapore, Singapore, 2National University of Singapore, Singapore, Singapore,

3Duke-NUS Medical School,

Singapore, Singapore, 4Institute of Mental Health, Singapore, Singapore,

5Health Promotion Board, Singapore, Singapore

PHP89 I6 COMPARISON BETWEEN THE EQ-5D-5L AND THE EQ-5D-3L FOR GENERAL POPULATION IN CHINA

Zhou T1, Guan HJ

2, Ma A

1, Liu GG

3,1China Pharmacuetical University, Nanjing, China,

2Peking University China Center for

Health Economic Research, Beijing, China, 3Peking University, Beijing, China

PHP90 I7 BUILDING INTENTIONS WITH THE THEORY OF PLANNED BEHAVIOUR: THE MEDIATING ROLE OF KNOWLEDGE AND EXPECTATIONS IN IMPLEMENTING NEW PHARMACEUTICAL SERVICES IN MALAYSIA

Tan CL1, Gan VB

2, Saleem F

3, Hassali MA

3,1Ministry of Health Malaysia, Seremban, Malaysia,

2Universiti Putra Malaysia,

Serdang, Malaysia, 3School of pharmaceutical sciences, Universiti Sains Malaysia, Penang, Malaysia

PHP91 I8 INDICATORS IN EVALUATING FINANCIAL AND ECONOMIC PERFORMANCE OF PHARMACY: A SYSTEMATIC REVIEW

Imani DA, Golestani M, Moghimi M, Janati A,Tabriz University of medical Sciences, Tabriz, Iran

PHP92 I9 ASSESSMENT OF HEALTH RELATED QUALITY OF LIFE OF HOSPITAL ADMITTED PATIENTS IN TERTIARY CARE HOSPITALS QUETTA BY USING SF-12 QUESTIONNAIRE

ul Haq N, Ali T, Nasim A, Razaq G, Riaz S, Yasmin R,University of Balochistan, Quetta, Pakistan

PHP93 I10 EVALUATION OF THE DIFFERENT PHARMACOECONOMIC MODELS ACROSS THE WORLD: A COMPARATIVE STUDY

Kotlo A, Muragundi PM,MCOPS Manipal University, Manipal, India

PHP94 J1 DEVELOPING A COMPREHENSIVE, CULTURALLY SENSITIVE CONCEPTUAL FRAMEWORK OF HEALTH DOMAINS IN SINGAPORE

Uy EJ1, Ow MY

2, Xin X

1, Sung SC

2, Cheung YB

2, Bautista D

2, Thumboo J

1,1Singapore General Hospital, Singapore,

Singapore, 2Duke-NUS Medical School, Singapore, Singapore

PHP95 J2 HOW MUCH ARE CHINESE WILLING TO PAY FOR THE HEALTH IMPROVEMENT?

Sun J, Sun L,Shenyang Pharmaceutical University, Shenyang, China

PHP96 J3 MY OPINIONS MATTER! HOW PERSPECTIVES, KNOWLEDGE AND EXPECTATIONS MATTER IN MODERATING THE SUCCESS OF NEW PHARMACEUTICAL SERVICES IMPLEMENTATION IN MALAYSIA

Tan CL1, Gan VB

2,1Ministry of Health Malaysia, Seremban, Malaysia,

2Universiti Putra Malaysia, Serdang, Malaysia

PHP98 J4 HEALTH STATE VALUATION IN SRI LANKA USING THE EQ-5D-3L; PRECURSOR TO QALY ESTIMATION IN SOUTH ASIA

Kularatna S1, Scuffham P

2,1Griffith University, Meadowbrook, Australia,

2Griffith University, Gold Coast, Australia

PHP99 J5 BILIRUBIN AND NEURODEGENERATIVE DISEASE PREVENTION

Muhsain SN1, Farooqui M

1, Lang M

2, Abu Bakar A

2,1Universiti Teknologi MARA, Kepala Batas, Malaysia,

2University of

Queensland, Coopers Plains, Australia

PHP100 J6 A COMPARATIVE ANALYSIS ON HEALTH SECURITY SYSTEM BETWEEN CHINA AND DEVELOPED COUNTRIES

Wu J1, Liu J

2, Zhu B

2, Mao Y

2,1City University of Hong Kong, Kowloon, Hong Kong,

2Xi'an Jiaotong University, Xi'an, China

PHP101 J7 EVALUATION OF ANTIBACTERIAL AND CYTOTOXIC EFFECTS OF GYMNEMA SYLVESTRE R.BR. SPECIES CULTIVATED IN PAKISTAN AGAINST COMMON RESISTANT PATHOGENS

Tahir M1, Anjum MS

2, Zahid Tanveer M

1, Iqbal MZ

3,1University of Veterinary and Animal Sciences, Lahore, Pakistan;, Lahore,

Pakistan, 2PMAS- Arid Agriculture University, Rawalpindi, Pakistan, Rawalpindi, Pakistan,

3AIMST University, Sungai Petani,

Malaysia

PHP102 J8 WHAT IS GOVERNMENT'S RESPONSIBILITY FOR CHINA'S UNIVERSAL HEALTH SECURITY? AN OUTLOOK FOR A NATIONAL HEALTH SECURITY SYSTEM

Wu J, Liu J, Zhu B, Mao Y,Xi'an Jiaotong University, Xi'an, China

PHP103 J9 APPLICATION OF HEALTHCARE FAILURE MODE & EFFECT ANALYSIS IN IMPROVING PATIENT EDUCATION AT AN OUTPATIENT DEPARTMENT OF A TERTIARY CARE HOSPITAL

Devarakonda S,Armed Forces Medical College, pune, India

PHP104 J10 TRENDS OF INCLUDING PHARMACOECONOMICS COURSE IN THE UNDERGRADUATE PHARMACY CURRICULUM

Thomas D, Sundararaj KG, Shirwaikar A,Gulf Medical University, Ajman, United Arab Emirates

PHP105 K1 THE IMPACT OF SURGICAL PROFESSIONAL EDUCATION: A REVIEW OF CLINICAL AND ECONOMIC OUTCOMES

Bourcet A1, Lim S

2, Metz L

1,1Johnson & Johnson Medical Asia Pacific, Singapore, Singapore,

2Costello Medical Singapore Pte

Ltd, Singapore, Singapore

HEALTH CARE USE & POLICY STUDIES - Health Technology Assessment Programs

PHP106 K2 HEALTH TECHNOLOGY ASSESSMENT SUPPORTS EVIDENCE-BASED DECISION-MAKING IN THE CHANGI GENERAL HOSPITAL MARKETPLACE EXERCISE

Pwee KH, Tong SC, Chow WL,Eastern Health Alliance, Singapore, Singapore

PHP107 K3 ECONOMIC EVALUATION GUIDELINE FOR PHARMACEUTICALS AND MEDICAL DEVICES IN JAPAN

Fukuda T1, Igarashi A

2, Ishida H

3, Ikeda S

4, Saito S

5, Sakamaki H

6, Shimozuma K

7, Shiroiwa T

1, Takura T

8, Tomita N

9, Noto S

10,

Fukuda H11

, Moriwaki K12

, Moriyama Y1, Akazawa M

13,1National Institute of Public Health, Wako, Japan,

2University of Tokyo,

Graduate School of Pharmaceutical Sciences, Tokyo, Japan, 3Yamaguchi University, Ube, Japan,

4International University of

Health and Welfare, Ohtawara, Japan, 5Okayama University, Okayama, Japan,

6Tokyo University of Science, Saitama,

Japan, 7Ritsumeikan University, Kusatsu, Japan,

8Osaka University, Osaka, Japan,

9National Institute of Public Health, Saitama,

Japan, 10

Niigata University of Health and Welfare, Niigata, Japan, 11

Kyushu University, Fukuoka, Japan, 12

Kobe Pharmaceutical University, Kobe, Japan,

13Meiji Pharmaceutical University, Tokyo, Japan

PHP108 K4 A QUANTITATIVE ANALYSIS OF HEALTH TECHNOLOGY ASSESSMENT (HTA) AGENCIES FOR ATTRIBUTES DRIVING TRANSPARENCY OF THE ORGANIZATION: COMPARISON OF SIX ASIA-PACIFIC HTA AGENCIES

Mazumder D1, Kapoor A

2, Gwatkin N

3, Medeiros C

4,1Optum, Greater Noida, India,

2Optum Global Solutions, Noida, India,

3Geni

Biopharma, Hampshire, UK, 4Optum Life Sciences, Minneapolis, MN, USA

PHP109 K5 SEGMENTATION OF SEVEN ASIA-PACIFIC HEALTH TECHNOLOGY ASSESSMENT (HTA) AGENCIES INTO DIFFERENT EVOLUTIONARY HTA ARCHETYPES

Mazumder D1, Kapoor A

2, Gwatkin N

3, Medeiros C

4,1Optum, Greater Noida, India,

2Optum Global Solutions, Noida, India,

3Geni

Biopharma, Hampshire, UK, 4Optum Life Sciences, Minneapolis, MN, USA

PHP110 K6 DETERMINING CRITERIA AND WEIGHTS FOR PRIORITISING HEALTH TECHNOLOGIES BASED ON THE PREFERENCES OF THE GENERAL POPULATION: A NEW ZEALAND PILOT STUDY

Sullivan T, Hansen P,University of Otago, Dunedin, New Zealand

PHP111 K7 COMPARISON OF ECONOMIC EVALUATION GUIDELINES BETWEEN JAPAN AND OTHER COUNTRIES

Millier A1, Cheng X

2, Onishi Y

3, Aballéa S

1, Toumi M

1, Doley J

1,1Creativ-Ceutical, Paris, France,

2Creativ-Ceutical, Hong Kong,

Hong Kong, 3Creativ-Ceutical K.K., Tokyo, Japan

PHP112 K8 LOCAL UTILITIES FOR LOCAL STUDIES: DATA AVAILABILITY AND METHODOLOGY IN JAPAN AND KOREA

Kim HR1, Chen X

1, Pyo J

2, Crawford B

3,1IMS Japan KK, Minato-ku, Tokyo, Japan,

2IMS Health Korea, Seoul, South Korea,

3IMS

Japan K.K., Minato-ku, Tokyo, Japan

PHP113 K9 REVIEW OF PRICING & INNOVATION IN KOREA & TAIWAN

Gambari J, Duttagupta S, Chowdhury CA,CBPartners, New York, NY, USA

PHP114 K10 A BARRIERS TO AND FACILITATORS OF THE USE OF HTA REPORTS BY POLICYMAKERS IN KAZAKHSTAN

Kostyuk A1, Akanov A

2, Nurgozhin T

3,1KazAHTA, Astana, Kazakhstan,

2Astana Medical University, Astana,

Kazakhstan, 3Nazarbayev University, National Laboratory Astana, Astana, Kazakhstan

PHP115 L1 TRENDS IN HEALTH TECHNOLOGY ASSESSMENTS SINCE THE INTRODUCTION OF COST-EFFECTIVENESS IN THE NETHERLANDS

Dvortsin E, Vondeling G, van der Woude T, Postma MJ,University of Groningen, Groningen, The Netherlands

HEALTH CARE USE & POLICY STUDIES - Population Health

PHP116 L2 SCIENTIFIC EPIDEMIOLOGY AND HEALTH ECONOMICS: A RETROSPECTIVE ANALYSIS ON PESTICIDE CONSUMPTION AND SURVIVORS IN TELANGANA STATE-INDIA

Banoth SL,Kakatiya University, Warangal, India

PHP117 L3 ESTIMATING THE CONTRIBUTION ON THE REDUCTION OF THE BURDEN OF IRON DEFICIENCY ANEMIA FROM THE CURRENT FORTIFICATION STRATEGY OF COMMERCIAL FOODS TARGETED TO INFANTS AND TODDLERS IN INDIA. SCENARIOS USING SYSTEMATIC REVIEW AND REAL WORLD EVIDENCE

Detzel P,Nestle Research Center, Lausanne, Switzerland

HEALTH CARE USE & POLICY STUDIES - Prescribing Behavior & Treatment Guidelines

PHP118 L4 HOW GIFTS AND BRAND REMINDERS INFLUENCE THE GENERIC BRAND SELECTION AMONG PHYSICIANS?

Muragundi PM, Bharath K, Udupa N,Manipal University, Manipal, India

PHP119 L5 EVALUATION OF SOCIAL SECURITY ORGANIZATION'(SSO) REGULATIONS ON PHYSICIAN PRESCRIBING PATTERN IN IRAN IN 2014

Soleymani F1, Kebriaeezadeh A

2,1Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of),

2Tehran University

of Medical Sciences, Faculty of Pharmacy, Tehran, Iran (Islamic Republic of)

PHP120 L6 USE OF CLINICAL INTELLIGENCE IN MONITORING RATIONAL DRUG USE INDICATORS IN THAILAND

Phraewphiphat R, Piebpien P, Bunupuradah P, Pattanaprateep O, Leelaudomlipi S,Faculty of Medicine Ramathibodi Hospital,

Mahidol University, Bangkok, Thailand

PHP121 L7 PROSPECTIVE STUDY OF THE INCIDENCE, NATURE AND CAUSES OF DISPENSING ERRORS IN COMMUNITY PHARMACIES OF ULAANBAATAR, MONGOLIA

Gendenragchaa B, Dorj G, Dorj G, Sanjjav T,Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia

HEALTH CARE USE & POLICY STUDIES - Quality of Care

PHP122 L8 THE ACCURACY OF PATIENT SELF REPORT IN MEASURING CONTINUITY OF CARE IN AUSTRALIA

Wright M,University Technology Sydney, Broadway, Australia

PHP123 L9 MEDICATION RECONCILIATION: A TOOL FOR BETTER PATIENT CARE

Vangaveti T1, Karimkuttickal NM

1, P SK

1, P SK

1, Vilakkathala R

2, Mallayasamy S

2, Stanley W

2,1Manipal College of

Pharmaceutical Sciences, Manipal, India, 2Manipal University, Manipal, India

HEALTH CARE USE & POLICY STUDIES - Regulation of Health Care Sector

PHP124 L10 INTERNATIONAL REFERENCE PRICING'S EVOLUTION IN CHINA

Guan Y,Sanofi China, Shanghai, China

PHP125 M1 A COMPARISON OF NATIONAL GUIDELINES FOR NETWORK META ANALYSIS

Laws AJ,Icon Plc, Vancouver, BC, Canada

HEALTH CARE USE & POLICY STUDIES - Risk Sharing/Performance-Based Agreements

PHP126 M2 PRICING AND MARKET ACCESS OF ORPHAN DRUGS IN CHINA: ANALYSIS OF NATIONAL AND PROVINCIAL POLICY AND THE ASSOCIATED IMPACT ON COVERAGE

Sherwin G, Akpinar P, Yap B,ICON plc, LONDON, UK

PHP127 M3 DEVELOPMENT OF HTA IN KAZAKHSTAN

Bektur C,Nazarbayev University, National Laboratory Astana, Astana, Kazakhstan

PHP128 M4 ADOPTION OF MANAGED ENTRY AGREEMENTS IN ESTABLISHED AND EMERGING MARKETS

Xue Y1, Montilva J

2, Degun R

1,1Navigant Consulting Inc, London, UK,

2Navigant Consulting, London, UK

PHP129 M5 ANALYSIS ON THE REGIONAL DISTRIBUTION OF TELEMEDICINE IN CHINA

Lu B,Shenyang Pharmaceutical University, shenyang,China, China

HEALTH CARE USE & POLICY STUDIES - Conceptual Papers

PHP130 M6 A CONCEPTUAL FRAMEWORK FOR TACKLING MARKET ACCESS CHALLENGES IN ASIA

Umareddy I,Kantar Health, Singapore, Singapore

PHP131 M7 UNDERSTANDING CONTINUITY OF CARE AT A PROVIDER AND PRACTICE LEVEL

Wright M,University Technology Sydney, Broadway, Australia

PHP132 M8 NEED OF COSMETOVIGILANCE IN INDIA

Udupa N, Ligade V,Manipal University, Manipal, India

PHP133 M9 USE OF HEALTH ECONOMIC INFORMATION IN THE MANAGEMENT OF HEALTH CARE RESOURCE ALLOCATION

Maharajan M1, Rajiah K

2, Sivanandy P

2,1International Medical University Malaysia, Kuala Lumpur, Malaysia,

2International

Medical University, Kuala Lumpur, Malaysia

PHP134 M10 DO NUTRITION INTERVENTIONS REQUIRE A DIFFERENT APPROACH TO ECONOMIC EVALUATION?

Drummond M1, Fattore G

2,1University of York, Heslington, York, UK,

2SDA-Bocconi School of Management, Centre for

Research in Healthcare Management (CERGAS), Milano, Italy

PHP135 N1 A CONCEPTUAL FRAMEWORK OF BASELINE EQUITY FOR RURAL BASIC MEDICAL INSURANCE IN CHINA: BASED ON POLICY PROCESS THEORY

Wu J, Liu J, Zhu B, Mao Y,Xi'an Jiaotong University, Xi'an, China

PHP136 N2 PRACTICE BASED OUTCOME RESEARCH IN COMMUNITY PHARMACY

Rajiah K, Maharajan M, Sivanandy P,International Medical University, Kuala Lumpur, Malaysia

DISEASE- SPECIFIC STUDIES

GASTROINTESTINAL DISORDERS - Clinical Outcomes Studies

PGI1 N3 A SYSTEMATIC REVIEW AND META-ANALYSIS ON TOLERABILITY AND EFFICACY OF SOFOSBUVIR CONTAINING REGIMENS IN HEPATITIS C PATIENTS WITH STAGE 4-5 CHRONIC KIDNEY DISEASE

Singhal R, Ahlawat R, Tiwari P,National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali),

Punjab, India

PGI2 N4 META-ANALYSIS OF THE EFFECTIVENESS ON PEGINTERFERON FOR CHRONIC HEPATITIS C

Chen PY1, Ma AX

2,1China pharmaceutical university, Nanjing, China,

2China Pharmaceutical University, Nanjing, China

GASTROINTESTINAL DISORDERS - Cost Studies

PGI3 N5 HOSPITAL ADMISSIONS AND COSTS OF CROHN'S DISEASE IN NEW ZEALAND AND THE IMPACT OF ADALIMUMAB

Milne RJ1, Gearry RB

2, Eglinton TW

2,1University of Auckland, Auckland, New Zealand,

2University of Otago at Christchurch,

Christchurch, New Zealand

PGI5 N7 TREATMENT COST ESTIMATION OF CHRONIC GASTRITIS CAUSED BY HELICOBACTER PYLORI

Odsuren M1, Sarantuya T

2, Undram L

3,1First Central Hospital of Mongolia, Ulaanbaatar, Mongolia,

2United Family Intermed

Hospital, Ulaanbaatar, Mongolia, 3Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia

PGI6 N8 A COST-UTILITY ANALYSIS OF DIFFERENT ANTIVIRAL MEDICINE REGIMENS IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 in Iran

Alavian SM1, Nikfar S

2, Kebriaeezadeh A

2, Rezaei Hemami M

3, Sanati E

2, Keshavarz K

4,1Baqiyatallah Research Center for

Gastroenterology and Liver Diseases, Tehran, Iran (Islamic Republic of), 2Tehran University of Medical Sciences, Faculty of

Pharmacy, Tehran, Iran (Islamic Republic of), 3University of Glasgow, Glasgow, UK,

4Shiraz University of Medical Sciences, School

of Management and Information Sciences, Shiraz, Iran (Islamic Republic of)

GASTROINTESTINAL DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

PGI7 N9 ESTIMATING UTILITIES FOR LIVER DISEASES USING STANDARD GAMBLE METHOD

Jo M, Ock M, Lim SY,University of Ulsan College of Medicine, Seoul, South Korea

PGI8 N10 A STUDY ON DRUG UTILIZATION AND DRUG RELATED PROPLEMS AMONG ANTI-ULCER PATIEND ADMITTED IN TEACHING HOSPITAL

Ramkanth S1, Thattakudian Sheikuduman MS

2, Thiruvengadarajan V

1, Chakka G

2,1Annamacharya College of Pharmacy, Kadapa,

India, 2Annamacharya College of Pharmacy, YSR Kadapa, India

PGI9 O1 ESTIMATION OF WILLINGNESS TO PAY FOR A QUALITY-ADJUSTED LIFE YEAR ON A CURE

Song HJ1, Lee E

2,1SungKyunKwan University, Suwon, South Korea,

2Sungkyunkwan University, Suwon, South Korea

GASTROINTESTINAL DISORDERS - Health Care Use & Policy Studies

PGI10 O2 THE FOLLOW-UP AND UTILIZATION OF DRUG TREATMENT FOR CHRONIC HBV/HCV PATIENTS WITH MAJOR PSYCHIATRIC DISEASES IN TAIWAN

Tsai C, Chang C, Tang C, Lin Y, Lu S,Taipei Medical University, Taipei, Taiwan

PGI11 O3 REAL LIFE DRUG UTILIZATION AND BIOLOGICS EFFECTIVENESS IN PATIENTS WITH CROHN'S DISEASE – A POPULATION-BASED STUDY IN TAIWAN

Smulders M1, Cheng C

2, Lien HP

3, Liang H

4, Khalid JM

5, Kao Yang Y

2,1SmartAnalyst, New York, NY, USA,

2National Cheng Kung

University, Tainan, Taiwan, 3Takeda Pharmaceuticals Taiwan, Ltd., Taipei, Taiwan,

4Takeda Development Center Americas, Inc,

Deerfield, IL, USA, 5Takeda Development Centre Europe Ltd, London, UK

PGI12 O4 POLICY EVALUATION ON“THE PAY-FOR-PERFORMANCE PROGRAM OF HEPATITIS B AND C” IN TAIWAN

Lu S, Tang C, Lin Y, Tsai C,Taipei Medical University, Taipei, Taiwan

PGI13 O5 THE ROLE OF INSULIN-LIKE GROWTH FACTOR-1 ON STEATOHEPATITIS

Bulur O, Dal K, Ertugrul dT, Aydoğan Y, Beyan E, Karadag I, Ünsal O,keçiören research hospital ANKARA /TURKEY, Ankara,

Turkey

PGI14 O6 HEART RATE RECOVERY IN İNFLAMMATORY BOWEL DISEASE (IBD)

Ünsal O, Karakaya S, Bulur O, Dal K, Uzman M, Eser M, Aydogan Y,keçiören research hospital ANKARA /TURKEY, Ankara,

Turkey

PGI15 O7 KNOWLEDGE, ATTITUDE AND PRACTICE TOWARDS HEPATITIS B AMONG MEDICAL COLLEGE STUDENTS OF QUETTA, PAKISTAN

ul Haq N1, Malik Z

1, Nasim A

1, Riaz S

1, Mohammad G

1, Azhar S

2,1University of Balochistan, Quetta, Pakistan,

2Comsats Institute

of Information Technology, Abbottabad, Pakistan

MENTAL HEALTH - Clinical Outcomes Studies

PMH1 O8 CLINICAL OUTCOMES OF BIPOLAR DISORDER ON LONG-TERM TREATMENT WITH LITHIUM WITH OR WITHOUT MOOD STABILIZERS

De Guzman GQ,Virgen Milagrosa University Foundation, San Carlos City, Pangasinan, Philippines

PMH2 O9 PREVALENCE AND CHARACTERISTICS OF MENTAL DISORDERS AMONG HOSPITALIZED BREAST CANCER PATIENTS IN THE UNITED STATES

Wang X, Xiao H,University of Florida, Gainesville, FL, USA

PMH3 O10 CROSS-VALIDATION OF A 7-ITEM CLINICAL DECISION RULE FOR DETECTING PANIC-RELATED ANXIETY IN EMERGENCY MEDICINE PATIENTS

Sung SC1, Rush AJ

1, Earnest A

2, Lim LE

3, Lim SH

3, Ong ME

3,1Duke-NUS Medical School, Singapore, Singapore,

2Monash

University, Melbourne, Australia, 3Singapore General Hospital, Singapore, Singapore

PMH4 P1 SOMATIC SYMPTOMS IN PATIENTS WITH UNDIAGNOSED DEPRESSION: PREVALENCE AND HEALTH CARE UTILIZATION IN JAPAN

Takahashi O, Ohde S,St.Luke's International University, Tokyo, Japan

PMH5 P2 CLINICAL EFFECTIVENESS TELEPSYCHOTHERAPY FOR DEPRESSION DISORDER: A SYSTEMATIC REVIEW

Park JJ1, Kim S

2, Park D

2,1National Evidence-based Collaborating Agency, Seoul, South Korea,

2National Evidence-based

Healthcare Collaborating Agency, Seoul, South Korea

PMH6 P3 COMPARATIVE EVALUATION OF SAFETY, EFFICACY AND COGNITIVE PROFILE OF AMISULPRIDE AND OLANZAPINE IN SCHIZOPHRENIA PATIENTS- A PROSPECTIVE STUDY

Ramesh S, Sivakumar P, Prashant C, Sivasankar M, Manikandhan C, Jai Ganesh KP,Nehru College of Pharmacy, Thrissur

District, India

PMH7 P4 PREVALENCE OF ANTICHOLINERGIC DRUG USE IN OLDER ADULTS WITH DEMENTIA

Ong YS, Fong TY, Chen LL, Chiang YY, Lim KW, Koh L, Mamun K,Singapore General Hospital, Singapore, Singapore

MENTAL HEALTH - Cost Studies

PMH8 P5 ESTIMATING THE ECONOMIC BURDEN OF TREATMENT RESISTANT DEPRESSION IN TAIWAN USING THE NHIRD

Klug J1, Yu F

2, Chang C

3, Juang H

4, Wang M

5, Fife D

6, Liu C

4, Wang BC

7,1Janssen Asia Pacific, Kowloon, Hong Kong,

2Janssen

Asia Pacific, Beijing, China, 3Chang Gung University, TaoYuan, Taiwan,

4Chang Gung Memorial Hospital, Tao-Yun,

Taiwan, 5Janssen Taiwan, Taipei, Taiwan,

6Janssen, pharmaceutical company of Johnson and Johnson, Titusville, NJ,

USA, 7Elysia Group Ltd, Taipei, Taiwan

PMH9 P6 ECONOMIC BURDEN OF SCHIZOPHRENIA IN CHINA: A LITERATURE REVIEW

Jia Y1, Cheng X

2, Aballea S

3, Dorey J

3, Toumi M

4,1Shenyang Pharmaceutical University, Shenyang, China,

2Creativ-Ceutical,

Hong Kong, Hong Kong, 3Creativ-Ceutical, Paris, France,

4Aix-Marseille University, Marseille, France

PMH10 P7 THE ECONOMIC BURDEN OF SCHIZOPHRENIA IN MALAYSIA

Teoh SL1, Chaiyakunapruk N

1, Chong HY

1, Aziz SA

2, Chemi N

2, Othman AR

2, Zaki NM

2, Vanichkulpitak P

3,1Monash University

Malaysia, Selangor, Malaysia, 2Hospital Kuala Lumpur, Kuala Lumpur, Malaysia,

3Silpakorn University, Nakhon Pathom, Thailand

PMH11 P8 ESTIMATED RANGE OF COST OF TREATMENT OF ADULT SCHIZOPHRENIA PATIENTS AT A TERTIARY HOSPITAL AS OF OCTOBER 2015

Abala AT, Bautista T,University of the Philippines-Philippine General Hospital, Manila, Philippines

PMH12 P9 A COST-EFFECTIVENESS ANALYSIS OF GUANFACINE EXTENDED-RELEASE TREATMENT IN PEDIATRIC ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

Maeda S, Shimozuma K, Takeda Y,Ritsumeikan University, Kusatsu, Japan

PMH13 P10 AN ECONOMIC MODEL OF ADVANCE CARE PLANNING: A COST EFFECTIVE INTERVENTION FOR PEOPLE WITH DEMENTIA

Nguyen K,Griffith University, Brisbane, Australia

PMH14 Q1 COST-UTILITY ANALYSIS EVALUATING VORTIOXETINE VERSUS VENLAFAXINE XR AND AGOMELATINE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN TAIWAN

Brignone M1, Atsou K

1, Reynaud-Mougin C

2, Chen W

3, Milea D

4,1Lundbeck SAS, Paris, France,

2H. Lundbeck A/S, Copenhagen,

Denmark, 3Hoan Pharmaceuticals Ltd., Taipei, Taiwan,

4Lundbeck Singapore Pte Ltd, Singapore, Singapore

PMH15 Q2 REAL-WORLD HEALTH OUTCOMES, ECONOMIC IMPACTS, AND COST-EFFECTIVEENESS OF A BEIJING MUNICIPAL GOVERNMENT FUNDED FREE-DRUG RPOGRAM IN COMMUNITY SCHIZOPHRENIA PATIENTS IN BEIJING, CHINA

Yan F1, Yang Y

2, Jia P

3, Huang Q

1, Chen Y

1, Du F

3, Yang Y

3, Chen W

3,1Beijing Anding Hospital of Capital Medical University,

Beijing, China, 2Beijing Municipal Commission of Health and Family Planning, Beijing, China,

3Beijing Community Services

Association, Beijing, China

PMH16 Q3 ESTIMATING THE ECONOMIC IMPACT DUE TO PRODUCTIVITY LOSSES OF DIABETES AND MAJOR DEPRESSIVE DISORDER IN SINGAPORE: HUMAN CAPITAL VERSUS FRICTION COST APPROACHES

Brooks-Rooney C1, Griffiths M

2, Chen G

1,1Costello Medical Singapore Pte Ltd, Singapore, Singapore,

2Costello Medical

Consulting Ltd, Cambridge, UK

MENTAL HEALTH - Patient-Reported Outcomes & Patient Preference Studies

PMH17 Q4 ASSESS THE MEDICATION ADHERENCE IN PATIENTS WITH SEVERE MENTAL ILLNESS ATTENDING PUBLIC TERTIARY CARE HOSPITALS OF QUETTA, PAKISTAN

ul Haq N1, Ahmed N

1, Rasool G

2, Illyas M

2, Nasim A

1,1University of Balochistan, Quetta, Pakistan,

2Baluchistan Institute of

Psychiatry and Behavioral Sciences, Quetta, Pakistan

PMH18 Q5 THE MEDICATION ADHERENCE IN SCHIZOPHRENIA MANAGEMENT BY USING SECOND GENERATION ANTIPSYCHOTICS IN TAIWAN: A POPULATION STUDY BASED ON NHRID

Chung C1, Tai TA

2, Chou KP

2,1Mackay Medical College, New Taipei City, Taiwan,

2IMS Health Taiwan, Taipei, Taiwan

PMH19 Q6 QUALITY OF LIFE MEASURED WITH EQ-5D IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN JAPAN

Sakurai K1, Yoshimura K

2, Arima H

3,1The University of Tokyo, Tokyo, Japan,

2Chiba University, Chiba, Japan,

3Shinagawa

Ekimae Mental Clinic, Tokyo, Japan

PMH22 Q7 ASSESSMENT OF HEALTH RELATED QUALITY OF LIFE (HRQOL) OF PATIENTS WITH SEVERE MENTAL ILLNESS ATTENDING TERTIARY CARE PUBLIC HOSPITALS OF QUETTA, PAKISTAN

ul Haq N1, Ahmed N

1, Rasool G

2, Illyas M

2, Nasim A

1,1University of Balochistan, Quetta, Pakistan,

2Baluchistan Institute of

Psychiatry and Behavioral Sciences, Quetta, Pakistan

MENTAL HEALTH - Health Care Use & Policy Studies

PMH23 Q8 IS THERE A DIFFERENCE IN PERCEPTION AND PRACTICE IN PHARMACOLOGICAL MANAGEMENT OF SCHIZOPHRENIA- A CROSS SECTIONAL SURVEY IN INDIA

Gundugurti PR1, Nagpal R

2, Sheth AS

3, Narang P

4, Gawande SJ

4, Sharma S

4, Klug J

5,1Asha Hospital, Hyderabad,

India, 2Manobal Klinik, New Delhi, India,

3Unlimited Potentialities, Mumbai, India,

4Johnson & Johnson India Private Limited,

Mumbai, India, 5Johnson & Johnson Hongkong, Kowloon, Hong Kong

PMH24 Q9 ASIANS' MENTAL HEALTH STATUS IN A U.S. MIDWESTERN METROPOLIS, 2004 -2013

Liu Y1, Cai J

2, Okah FA

3,1University of Missouri–Kansas City, Kansas City, MO, USA,

2Kansas City Health Department, Kansas

City, MO, USA, 3University of Missouri - Kansas City, Kansas City, MO, USA

PMH25 Q10 TREATMENT RESISTANT DEPRESSION DEVELOPMENT FROM MAJOR DEPRESSIVE DISORDER: A CLAIMS DATABASE ANALYSIS IN JAPAN

Tsukazawa SK1, Fife D

2, Shimamoto K

3, Mahlich J

1,1Janssen Pharmaceuticals KK, Tokyo, Japan,

2Janssen, pharmaceutical

company of Johnson and Johnson, Titusville, NJ, USA, 3MediStatLab, Tokyo, Japan

PMH26 R1 EXERCISE AND FACTORS INFLUENCE MENTAL HEALTH OF UNDERGRADUATED STUDENTS AT BURAPHA UNIVERSITY IN 2014

Phanudulkitti C, Nawkij P, Sungkaeo A, Thanmarak P, Auamnoy T,Burapha University, Chonburi, Thailand

SENSORY SYSTEMS DISORDERS - Clinical Outcomes Studies

PSS1 R2 LONG-TERM FOLLOW-UP OF RANIBIZUMAB TREATED PATIENTS WITH MYOPIC CHOROIDAL NEOVASCULARIZATION FROM THE RADIANCE CLINICAL TRIAL IN FOUR EAST ASIAN COUNTRIES

Skelly A1, Lara N

2, Pedros M

2, Macfadden W

3,1Novartis Ireland Limited, Dublin, Ireland,

2IMS Health, Barcelona, Spain,

3Novartis

Pharma AG, Basel, Switzerland

SENSORY SYSTEMS DISORDERS - Cost Studies

PSS2 R3 SENSITIVITY ANALYSIS OF ANTIBIOTIC COST IN CHRONIC SUPPURATIVE OTITIS MEDIA PATIENTS IN SOUTH INDIA: A RETROSPECTIVE OBSERVATIONAL STUDY

Kumar S1, Jayachandran L

1, Kumar A

1, A S

1, R B

2,1Manipal University, Manipal, India,

2Manipal university, Manipal, India

PSS3 R4 ANALYSIS OF TWO PRESSURE ULCER DRESSINGS FOR COST REDUCTION IN THE BRAZILIAN PUBLIC HEALTH SYSTEM

Tolentino AC1, Dick S

2, Amaya R

3,1Hospital Universitario Pedro Ernesto - UERJ/HUPE, Rio de Janeiro, Brazil,

2The College Of

St. Scholastica, Duluth, MN, USA, 3Pediatric Wound Care & Laser Specialists, Houston, TX, USA

PSS4 R5 APPLICATION OF VALUE OF INFORMATION ANALYSIS TO MINIMIZE DECISION RISK IN MALAYSIA

Chong HY1, Wu BC

2, Chaiyakunapruk N

1,1Monash University Malaysia, Selangor, Malaysia,

2Ministry of Health Singapore,

Singapore, Singapore

SENSORY SYSTEMS DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

PSS5 R6 BARRIERS TO INTRAVITREAL INJECTION THERAPY ADHERENCE IN DME PATIENTS IN AUSTRALIA

Schnabel R1, Tan J

2, Cullip T

3, Guinan G

3, Cameron C

1,1Allergan Australia Pty Ltd, Gordon, Australia,

2Allergan Pte Ltd,

Singapore, Singapore, 3So What Research Pty Ltd, Potts Point, Australia

PSS6 R7 ASSESSING THE OUTCOMES OF PROSTHETIC TREATMENT IN LOWER OVERDENTURE WEARERS

Kordiyak A, Bratus-Hrynkiv R,Danylo Halytskyi Lviv National Medical University, Lviv, Ukraine

PSS7 R8 PREDICTED DEMAND FOR A NEW INJECTABLE SOLUTION FOR DELIVERING GLAUCOMA MEDICINE

Ozdemir S1, Wong T

2, Finkelstein EA

3,1Duke-NUS Medical School, Singapore, Singapore,

2Singapore National Eye Centre,

Singapore, Singapore, 3Duke NUS Medical School, Singapore, Singapore

PSS8 R9 Fabrication and Characterization of Anti-Vitiligo Cream containing 5% Hydroalchohlic Extract of Psoralia Corylifolia.

Hussain I1, Hussain N

2, Manan A

1, Ali B

3, Rashid A

4,1SMBB Medical University, Larkana, Larkana, Pakistan,

2BZU, Multan,

Multan, Pakistan, 3Gomal University, Dera Ismail Khan, Pakistan,

4DRAP Pakistan, Islamabad, Pakistan

PSS9 R10 THE EFFECT OF TRADITIONAL MEDICINE ON QUALITY OF LIFE IN PATIENTS WITH ATOPIC DERMATITIS: A REVIEW OF RECENT CLINICAL TRIALS

Ko Y, Cheon C, Jang B, Ko S,Kyung Hee University, Seoul, South Korea

SENSORY SYSTEMS DISORDERS - Health Care Use & Policy Studies

PSS10 S1 DRUG UTILIZATION EVALUATION OF AMOXICILLIN-CLAVULANIC ACID IN CSOM PATIENTS IN A SOUTH INDIAN HOSPITAL: A RETROSPECTIVE ANALYSIS

Jayachandran L1, Kumar A

1, Kumar S

1, R B

2, A S

1,1Manipal University, Manipal, India,

2Manipal University, Udupi, India

PSS11 S2 ANTIMICROBIAL SUSCEPTIBILITY PATTERN IN CHRONIC SUPPURATIVE OTITIS MEDIA PATIENT IN A TERTIARY CARE HOSPITAL

Kumar A1, Jayachandran L

1, Kumar S

2, R B

3, A S

2,1Manipal university, Manipal,udipi, India,

2Manipal University, Manipal,

India, 3Manipal university, Manipal, India

URINARY/KIDNEY DISORDERS - Clinical Outcomes Studies

PUK1 S3 BURDEN OF CHILDHOOD ONSET CHRONIC KIDNEY DISEASE

Hsu C1, Tain Y

2,1Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan,

2Kaohsiung Chnag Gung Memorial Hospital,

Kaohsiung, Taiwan

PUK2 S4 CLINICAL EFFECTIVENESS OF CARBAPENEM VERSUS ALTERNATIVE ANTIBIOTICS FOR URINARY TRACT INFECTION DUE TO ENTEROBACTERIACEAE PRODUCING ESBL: A SYSTMATIC REVIEW

Park JJ1, Rhee J

2, Park D

2,1National Evidence-based Collaborating Agency, Seoul, South Korea,

2National Evidence-based

Healthcare Collaborating Agency, Seoul, South Korea

PUK3 S5 ETIOLOGY AND OUTCOME OF ACUTE KIDNEY INJURY IN SOUTH INDIAN POPULATION

Zabiuddin Ahad M1, Suresh AA

1, Kumar P

1, Attur RP

2,1Manipal College of Pharmaceutical Sciences, Manipal, India,

2Department

of Nephrology, Kasturba Medical College, Manipal University, Manipal, India

URINARY/KIDNEY DISORDERS - Cost Studies

PUK4 S6 ESTIMATING THE COST OF END-STAGE RENAL DISEASE TO THE HOSPITAL SYSTEM IN SINGAPORE

Sidharta SD1, Yang F

2, Yoong JS

1,1National University of Singapore, Singapore, Singapore,

2University of Manchester,

Manchester, UK

PUK5 S7 COMPARATIVE ANALYSIS ON THE OUT-OF-POCKET EXPENDITURE AMONG PATIENTS SUFFERING FROM CHRONIC KIDNEY DISEASE BETWEEN MEDICAL INSURANCE COVERED AND UNCOVERED AREAS IN CHINA

Wu J, Liu J, Zhu B, Mao Y,Xi'an Jiaotong University, Xi'an, China

PUK6 S8 PHARMACOECONOMIC EVALUATION OF PATIENTS UNDERGOING HEMODIALYSIS AT A TERTIARY CARE CENTRE

Prasad S, Kaza S, Prasad N S, Prabhu RA, Rangaswamy D, Shenoy S, Saraf K,Kasturba Medical College Manipal, Manipal

University, Manipal, Udupi, Karnataka, India

PUK7 S9 COST-EFFECTIVENESS OF A COMBINATION OF RENIN-ANGIOTENSIN SYSTEM INHIBITORS (RAS)/CALCIUM CHANNEL BLOCKERS (CCB) OR RAS MONOTHERAPY TO RETARD PROGRESSION OF KIDNEY DISEASE IN MALAYSIA

Mohd Tahir NA1, Thomas P

2, Makmor Bakry M

3, Abdul Gafor AH

4, Li SC

1,1University of Newcastle, Callaghan, NSW,

Australia, 2Taylor's University, Selangor, Malaysia,

3Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia,

4Universiti

Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia

PUK8 S10 COST EFFECTIVENESS OF OVERACTIVE BLADDER TREATMENT WITH MIRABEGRON IN PATIENTS IN SOUTH KOREA

Suh D1, Lee S

1, Lim SJ

1, Song J

1, Ko G

2,1Chung-Ang University, Seoul, South Korea,

2Astellas Pharma Inc., Seoul, South Korea

URINARY/KIDNEY DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

PUK10 T1 PATIENT ENGAGEMENT: TO SUPPORT MEDICATION ADHERENCE IN KIDNEY TRANSPLANTATION

Low JK1, Crawford K

1, Manias E

2, Williams A

1,1Monash University, Clayton, Australia,

2Deakin University, Burwood, Australia

PUK11 T2 LONGITUDINAL TRAJECTORIES OF DEPRESSIVE AND ANXIOUS SYMPTOMS FOLLOWING A SELF-MANAGEMENT INTERVENTION FOR HAEMODIALYSIS PATIENTS

Lam KF1, Mooppil N

2, Ng HJ

1, Kang AW

1, McBain H

3, Newman S

3, Griva K

1,1Department of Psychology, Faculty of Arts and

Social Sciences, National University of Singapore, Singapore, Singapore, 2National Kidney Foundation, Singapore, Singapore,

Singapore, 3School of Health Sciences, City University London, London, UK

PUK12 T3 PROGRESSION AND OUTCOMES OF NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE PATIENTS

Khan YH1, Sarriff A

1, Adnan AS

2, Khan AH

1, Mallhi TH

3,1Universiti Sains Malaysia, Pulau Pinang, Malaysia,

2University Sains

Malaysia, Kota Bharu, Malaysia, 3University Sains Malaysia, Pulau Penang, Malaysia

PUK13 T4 QUALITY OF LIFE FOR PATIENTS USING HEMODIALYSIS (HD) VS. PERITONEAL DIALYSIS (PD) MODALITIES IN TAIWAN

Kuo C, Hsieh W, Tang C,Taipei Medical University, Taipei, Taiwan

URINARY/KIDNEY DISORDERS - Health Care Use & Policy Studies

PUK14 T5 CLINICAL PROFILE AND MANAGEMENT OF CHRONIC KIDNEY DISEASE IN INDIAN GERIATRIC PATIENTS AT A PUBLIC TERTIARY CARE HOSPITAL: A CROSS-SECTIONAL STUDY

Tiwari P1, Ahlawat R

1, D'Cruz S

2,1National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali),

Punjab, India, 2Government Medical College & Hospital, Chandigarh, India

PUK15 T6 MANAGEMENT AND OUTCOMES OF ACUTE KIDNEY INJURY

Kumar P1, Suresh AA

1, Ahad MZ

1, Attur RP

2,1Manipal College Of Pharmaceutical Sciences, Manipal, India,

2Department of

Nephrology, Kasturba Medical College, Manipal University, Manipal, India

PUK16 T7 STOCK REDUCTION OF ERYTHROPOIETIN FOR PATIENTS ON HEMODIALYSIS AT SOMDECH PHRA DEBARATANA MEDICAL CENTER

Inmuanghiranchot S, Supapsophon P, Aim-oat A, Lohvithee P, Chandraruangnabha Y, Piluk W,Ramathibodi hospital, Bangkok,

Thailand